Polarean Imaging Partners with UVA Health for Clinical Xenon MRI Expansion

Polarean Imaging ( (GB:POLX) ) just unveiled an announcement.

Polarean Imaging has entered into a new supply agreement with the University of Virginia Health to implement full clinical Xenon MRI capabilities. This partnership marks a significant step in advancing pulmonary imaging, as UVA Health, a leader in Xenon MRI research, prepares to launch its first clinical Xenon MRI scan. The collaboration aims to enhance the evaluation and treatment of lung diseases, aligning with Polarean’s mission to provide critical imaging solutions for chronic lung disease.

The most recent analyst rating on (GB:POLX) stock is a Buy with a £0.04 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.

Spark’s Take on GB:POLX Stock

According to Spark, TipRanks’ AI Analyst, GB:POLX is a Neutral.

Polarean Imaging’s overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. The negative valuation metrics further weigh down the score. Although recent corporate events are positive, they are not enough to offset the significant financial and technical challenges.

To see Spark’s full report on GB:POLX stock, click here.

More about Polarean Imaging

Polarean Imaging is a revenue-generating medical imaging technology company that focuses on revolutionizing pulmonary medicine by introducing MRI technology to assess lung function. The company has developed the first FDA-approved hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW®, and is dedicated to researching, developing, and commercializing innovative imaging solutions for chronic respiratory diseases.

YTD Price Performance: -62.26%

Average Trading Volume: 4,869,427

Technical Sentiment Signal: Sell

Current Market Cap: £6.04M

Find detailed analytics on POLX stock on TipRanks’ Stock Analysis page.